¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"mixed lymphocyte response"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • biological response modifier
    »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦, »ýü¹ÝÀÀÁ¶Àý¹°Áú
  • brain stem evoked response audiometry
    ³úÁÙ±âÀ¯¹ß¹ÝÀÀû·Â°Ë»ç
  • concentration-response curve
    ³óµµ¹ÝÀÀ°î¼±
  • conditioned response
    Á¶°Ç¹ÝÀÀ
  • consummatory response
    ¼ºÃë¹ÝÀÀ
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • chemotactic response
    È­ÇÐÁÖ¼º¹ÝÀÀ, È­Çнò¸²¹ÝÀÀ
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • evoked response
    À¯¹ß¹ÝÀÀ
  • evoked response audiometry
    À¯¹ß¹ÝÀÀû·Â°Ë»ç
  • frequency response curve
    Á֯ļö¹ÝÀÀ°î¼±
  • galvanic skin response
    Àü±âÇǺιÝÀÀ
  • galvanic skin response audiometry
    ÇǺÎÀü±â¹ÝÀÀû·Â°Ë»ç
  • heat shock response
    ¿­Ãæ°Ý¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • mixed tumor
    È¥ÇÕÁ¾¾ç
  • mixed vaccine
    È¥ÇÕ¹é½Å
  • mixed germ cell tumor
    È¥ÇÕ¹è¾Æ¼¼Æ÷Á¾¾ç
  • mixed order reaction
    È¥ÇÕÂ÷¹ÝÀÀ
  • mixed suspended solid
    È¥ÇÕºÎÀ¯°íÇü¹°
  • alerting response
    °¢¼º¹ÝÀÀ
  • anamnestic response
    (¢¡secondary immune response) ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • arousal response
    °¢¼º¹ÝÀÀ
  • autoimmune response
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • brainstem evoked response audiometry
    ³úÁÙ±âÀ¯¹ß¹ÝÀÀû·Â°Ë»ç
  • evoked response audiometry
    À¯¹ß¹ÝÀÀû·Â°Ë»ç
  • galvanic skin response audiometry
    ÇǺÎÀü±â¹ÝÀÀû·Â°Ë»ç
  • startle response audiometry
    ³î¶÷¹ÝÀÀû·Â°Ë»ç
  • stimulus response assessment
    ÀڱعÝÀÀÆò°¡
  • biologic response modifier
    »ýü¹ÝÀÀÁ¶Àý¹°Áú, »ý¹°ÇÐÀû¹ÝÀÀÁ¶ÀýÁ¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • immune response, primary
    ÀÏÂ÷¸é¿ª¹ÝÀÀ
  • immune response, secondary
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • immunologic response
    ¸é¿ª¹ÝÀÀ.
  • immunological response
    ¸é¿ªÇÐÀû¹ÝÀÀ
  • inert response
    ºÒȰ¼º ¹ÝÀÀ
  • inspiratory triggering response time
    Èí±âÀ¯¹ß¹ÝÀÀ½Ã°£.
  • placebo response
    Çö󼼺¸¹ÝÀÀ, À§¾à¹ÝÀÀ, ¼ÓÀÓ¾à¹ÝÀÀ.
  • placebo response
    Çö󼼺¸¹ÝÀÀ, À§<°¡>¾à¹ÝÀÀ.
  • positive placebo response
    Çö󼼺¸Ä¡·á È¿°ú.
  • pressure response
    À½¾Ð¹ÝÀÀ(ëåäâÚãëë).
  • primary antibody response
    ÀÏÂ÷Ç×ü¹ÝÀÀ
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ(¡­Øóæ¹Úãëë).
  • primary immune response
    ÀÏÂ÷¸é¿ª¹ÝÀÀ(¡­Øóæ¹Úãëë).
  • radiation response
    ¹æ»ç¼±¹ÝÀÀ
  • recruiting response
    µ¿¿ø¹ÝÀÀ(ÔÑê¬Úãëë).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • reticular lymphocyte
    ¸Á»ó¸²ÇÁ±¸
  • sensitized lymphocyte
    °¨ÀÛ¸²ÇÁ±¸.
  • sensitized lymphocyte
    °¨ÀÛ¸²ÇÁ±¸(Êïí¡­Ï¹)
  • small lymphocyte
    ¼Ò¸²ÇÁ±¸
  • small lymphocyte
    ÀÛÀº¸²ÇÁ±¸, ¼Ò¸²ÇÁ±¸.
  • small lymphocyte
    ÀÛÀº¸²ÇÁ±¸
  • thymic derived lymphocyte
    Èä¼± À¯·¡ ¸²ÇÁ±¸
  • thymic lymphocyte
    °¡½¿»ù¼¼Æ÷, Èä¼±¸²ÇÁ?
  • tumor infiltration lymphocyte
    Á¾¾çħÀ±¸²ÇÁ±¸
  • age-response function
    ¿¬·É¹ÝÀÀÇÔ¼ö
  • alerting response
    °¢¼º¹ÝÀÀ(ÊÆá¥Úãëë)
  • allergic response
    ¾Ë·¹¸£±â¹ÝÀÀ, °ú¹Î¹ÝÀÀ
  • analytical response detection
    ºÐ¼®¹ÝÀÀ°¨Áö
  • anamnestic response
    ¸é¿ª[ÇÐÀû]±â¾ï[Çö»ó]¹ÝÀÀ
  • antibody response
    Ç×ü¹ÝÀÀ(¡­Úãëë).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HLA-LD human lymphocyte antigen-lymphocyte defined
LD labor and delivery; laboratory data; labyrinthine defect; lactate dehydrogenase; laser Doppler; lear...
PLT pancreatic lymphocytic infiltration; platelet; primed lymphocyte test; primed lymphocyte typing; psi...
CER capital expenditure review; ceramide; conditioned emotional response; control electrical rhythm; cor...
CR calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
MMMT Malignant mixed Mullerian tumor
MAR Mixed Anti-Globulin Reaction
MC Mixed Cellularity
M.C.T.D. Mixed Connective Tissue Disease
MC Mixed Cryoglobulinemia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antibody response
    Ç×ü ¹ÝÀÀ
  • approximate response
    ±Ù»ç ¹ÝÀÀ
  • attachment response
    ¾ÖÂø ¹ÝÀÀ
  • attention response
    ÁÖÀÇ·Â ¹ÝÀÀ
  • biologic response modifier
    »ýü ¹ÝÀÀ º¯ÇüÀÚ
  • CNS ischemic response
    ÁßÃß ½Å°æ ÇãÇ÷ ¹ÝÀÀ
  • concentration-response curve
    ³óµµ ¹ÝÀÀ °î¼±
  • conditioned fear response
    Á¶°ÇÈ­ °øÆ÷ ¹ÝÀÀ
  • dorsal horn response
    ¹è°¢ ¹ÝÀÀ
  • dose response relationship
    ¹æ»ç¿ë·® ¹ÝÀÀ °ü°è, ¿ë·® ¹ÝÀÀ °ü°è
  • dose-response curve
    ¿ë·® ¹ÝÀÀ °î¼±
  • emotional defense response
    Á¤¼­Àû ¹æ¾î ¹ÝÀÀ
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • evoked response
    À¯¹ß ¹ÝÀÀ
  • humoral immunologic response
    ü¾×¼º ¸é¿ª ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
lymphoma, mixed-cell, follicular A low-grade malignant lymphoma of follicular pattern in which there is no clear preponderance of one cell type (small or large) over another. The large cells, cleaved or noncleaved, are often 2-3 times larger in diameter than normal lymphocytes.
(12 Dec 1998)
antigens, differentiation, b-lymphocyte Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumours of B-cell origin.
(12 Dec 1998)
antigens, differentiation, t-lymphocyte Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function.
(12 Dec 1998)
bare lymphocyte syndrome <syndrome> Absence of HLA antigens on peripheral mononuclear cells, which may result in immunodeficiency.
(05 Mar 2000)
B lymphocyte <haematology, immunology> An immunologically important lymphocyte, produced by the bone marrow, that is responsible for the production of immunoglobulins, it is the precursor of the plasma cell.
The surface markers can be used to detect and differentiate chronic lymphocytic leukaemia from acute lymphocytic leukaemia.
(13 Nov 1997)
b-lymphocyte subsets A classification of B-lymphocytes based on structurally or functionally different populations of cells.
(12 Dec 1998)
gene rearrangement, b-lymphocyte Ordered rearrangement of b-lymphocyte variable gene regions coding for the immunoglobulin chains, thereby contributing to antibody diversity. It occurs during the differentiation of the immature b-lymphocyte.
(12 Dec 1998)
gene rearrangement, b-lymphocyte, heavy chain Ordered rearrangement of b-lymphocyte variable gene regions thereby contributing to antibody diversity. It occurs during the first stage of differentiation of the immature b-lymphocyte.
(12 Dec 1998)
gene rearrangement, b-lymphocyte, light chain Ordered rearrangement of b-lymphocyte variable gene regions coding for the kappa or lambda light chains, thereby contributing to antibody diversity. It occurs during the second stage of differentiation of the immature b-lymphocyte.
(12 Dec 1998)
gene rearrangement, t-lymphocyte Ordered rearrangement of T-cell variable gene regions coding for the antigen receptors.
(12 Dec 1998)
receptors, lymphocyte homing Cell surface glycoproteins on lymphocytes and other leukocytes that mediate adhesion to specialised blood vessels called high endothelial venules. Several different classes of lymphocyte homing receptors have been identified, and they appear to target different surface molecules (addressins) on high endothelial venules in different tissues. The adhesion plays a crucial role in the trafficking of lymphocytes.
(12 Dec 1998)
virgin lymphocyte <haematology, immunology> A lymphocyte that has not and whose precursors have not, encountered the antigenic determinant for which it possesses receptors.
(18 Nov 1997)
CD4 lymphocyte A specific type of lymphocyte, derived from the thymus gland, that plays an important role in cellular immunity. T4 lymphocytes (CD4 cells) are decreased (absolute counts less than 200) in patients with AIDS resulting in compromised immune function.
(27 Sep 1997)
CD4 lymphocyte count A count of the number of CD4-positive lymphocytes in the blood. Determination requires the use of a fluorescence-activated flow cytometer.
(12 Dec 1998)
Rieder's lymphocyte An abnormal form of lymphocyte that has a greatly indented (or lobed), slightly twisted nucleus; such cells are usually observed in certain examples of chronic lymphocytic leukaemia.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á